| Working Paper |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Benefits and Costs of Newer Drugs: An Update |
2 |
4 |
18 |
225 |
5 |
14 |
48 |
527 |
| CONTRIBUTIONS TO FEDERAL ELECTION CAMPAIGNS BY GOVERNMENT CONTRACTORS |
0 |
0 |
0 |
1 |
4 |
8 |
13 |
841 |
| CROWDING OUT: THE IMPACT OF THE STRATEGIC DEFENSE INITIATIVE ON U.S. CIVILIAN R&D INVESTMENT AND INDUSTRIAL COMPETITIVENESS |
0 |
0 |
0 |
0 |
0 |
0 |
6 |
820 |
| Computer Use and Productivity Growth in Federal Government Agencies, 1987 to 1992 |
0 |
1 |
11 |
173 |
9 |
20 |
103 |
1,224 |
| Computer Use and Productivity Growth in federal Government Agencies |
0 |
0 |
0 |
0 |
33 |
77 |
156 |
1,011 |
| Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act |
0 |
2 |
17 |
126 |
4 |
13 |
65 |
575 |
| Errors of Measurement in Output Deflators |
1 |
1 |
3 |
33 |
1 |
3 |
23 |
168 |
| GOVERNMENT SUBSIDIES TO PRIVATE MILITARY R&D INVESTMEN: DOD'S IR&D POLICY |
0 |
0 |
0 |
1 |
1 |
3 |
15 |
645 |
| Government Subsidies to Private Military R&D Investment: DOD's IR&D Policy |
1 |
4 |
11 |
69 |
5 |
17 |
84 |
313 |
| HOW ELASTIC IS THE GOVERNMENT'S DEMAND FOR WEAPONS? |
0 |
0 |
0 |
0 |
1 |
2 |
11 |
339 |
| Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003 |
0 |
2 |
11 |
31 |
1 |
5 |
42 |
103 |
| How Elastic is the Government's Demand for Weapons? |
0 |
4 |
6 |
15 |
3 |
15 |
41 |
124 |
| IR&D Project Data and Theories of R&D Investment |
3 |
4 |
12 |
56 |
4 |
14 |
48 |
217 |
| Importation and Innovation |
1 |
1 |
5 |
48 |
3 |
7 |
26 |
188 |
| Industrial De-Diversification and Its Consequences for Productivity |
0 |
2 |
7 |
92 |
5 |
8 |
27 |
295 |
| Industrial De-Diversification and its Consequences for Productivity |
2 |
4 |
9 |
42 |
7 |
13 |
39 |
161 |
| International R&D Spillovers: A Re-Examination |
1 |
7 |
28 |
358 |
4 |
19 |
73 |
852 |
| Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability |
0 |
0 |
3 |
16 |
0 |
2 |
12 |
86 |
| Ownership Structure and Corporate Performance in Japan |
2 |
8 |
28 |
155 |
7 |
28 |
98 |
440 |
| Pharmaceutical Innovation, Mortality Reduction, and Economic Growth |
2 |
4 |
22 |
317 |
5 |
16 |
80 |
1,414 |
| Pharmaceutical innovation and the longevity of Australians: a first look |
1 |
2 |
12 |
40 |
3 |
11 |
47 |
101 |
| Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health" |
1 |
5 |
16 |
197 |
8 |
28 |
84 |
744 |
| Private Investment in R&D to Signal Ability to Perform Government Contracts |
0 |
1 |
3 |
10 |
1 |
4 |
18 |
84 |
| R and D and Productivity at the Industry Level: Is There Still a Relationship? |
2 |
5 |
15 |
214 |
6 |
12 |
38 |
504 |
| R&D Investment and International Productivity Differences |
8 |
16 |
55 |
182 |
19 |
56 |
180 |
464 |
| Sources of U.S. Longevity Increase, 1960 -1997 |
0 |
1 |
9 |
44 |
6 |
9 |
37 |
514 |
| Sources of U.S. Longevity Increase, 1960-1997 |
2 |
4 |
20 |
160 |
6 |
17 |
81 |
870 |
| Spurious correlation in estimation of the health production function: A note |
5 |
13 |
48 |
48 |
19 |
47 |
118 |
118 |
| THE EFFECT OF TAKEOVERS ON THE EMPLOYMENT AND WAGES OF CENTRAL-OFFICE AND OTHER PERSONNEL |
0 |
0 |
0 |
1 |
1 |
2 |
11 |
381 |
| Technical Change, Learning, and Wages |
0 |
2 |
5 |
19 |
0 |
4 |
17 |
82 |
| The Allocation of Publically-Funded Biomedical Research |
1 |
3 |
7 |
61 |
6 |
16 |
36 |
950 |
| The Allocation of Publicly-Funded Biomedical Research |
3 |
4 |
8 |
35 |
5 |
10 |
22 |
449 |
| The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey |
0 |
1 |
3 |
52 |
1 |
3 |
9 |
310 |
| The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey |
0 |
2 |
5 |
169 |
4 |
9 |
24 |
618 |
| The Comparative Advantage of Educated Workers in Implementing New Technology: Some Empirical Evidence |
1 |
4 |
9 |
73 |
2 |
15 |
39 |
342 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry |
1 |
2 |
13 |
245 |
10 |
19 |
72 |
663 |
| The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US |
2 |
2 |
7 |
8 |
3 |
7 |
22 |
24 |
| The Effect Of Takeovers On The Employment And Wages Of Central-Office And Other Personnel |
0 |
2 |
5 |
311 |
5 |
16 |
36 |
863 |
| The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output |
0 |
0 |
4 |
58 |
0 |
1 |
9 |
298 |
| The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program |
0 |
0 |
2 |
33 |
1 |
6 |
41 |
280 |
| The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs |
3 |
5 |
14 |
89 |
13 |
32 |
94 |
545 |
| The Effect of New Drugs on Mortality from Rare Diseases and HIV |
1 |
1 |
9 |
73 |
2 |
4 |
24 |
505 |
| The Effect of New Political Administration on Federal Government Productivity and Employment |
0 |
1 |
9 |
108 |
5 |
22 |
103 |
903 |
| The Effect of New Political Administration on Federal Government Productivity and Employment |
0 |
0 |
0 |
1 |
0 |
4 |
15 |
397 |
| The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality |
3 |
4 |
13 |
135 |
9 |
16 |
47 |
461 |
| The Effect of Takeovers on the Employment and Wages of Central-Office and Other Personnel |
1 |
5 |
16 |
141 |
2 |
9 |
43 |
309 |
| The Effects Of Leveraged Buyouts On Productivity And Related Aspects Of Firm Behavior |
3 |
17 |
55 |
884 |
10 |
35 |
126 |
2,024 |
| The Effects of Leveraged Buyouts on Productivity and Related Aspects of Firm Behavior |
4 |
10 |
49 |
368 |
13 |
24 |
96 |
839 |
| The Effects of Mergers on Prices, Costs, And Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 |
0 |
1 |
4 |
259 |
0 |
2 |
20 |
528 |
| The Effects of Mergers on Prices, Costs, and Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 |
0 |
0 |
2 |
45 |
1 |
2 |
20 |
272 |
| The European Strategic Program for Research in Information Technologie (ESPRIT): An Ex-Post Analysis |
0 |
0 |
0 |
0 |
9 |
19 |
55 |
761 |
| The Expanding Pharmaceutical Arsenal in the War on Cancer |
1 |
2 |
13 |
97 |
4 |
9 |
31 |
306 |
| The Impact and Organization of Publicly-Funded Research and Development in the European Community |
0 |
3 |
10 |
106 |
7 |
17 |
70 |
774 |
| The Impact of Hospital Quality-Related Practices on Health Outcomes |
0 |
1 |
7 |
34 |
1 |
6 |
22 |
161 |
| The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data |
0 |
3 |
7 |
32 |
7 |
18 |
74 |
241 |
| The Impact of New Laboratory Procedures and Other Medical Innovations on the Health of Americans, 1990-2003: Evidence from Longitudinal, Disease-Level Data |
0 |
0 |
1 |
29 |
1 |
6 |
21 |
184 |
| The Impact of R&D Investment On Productivity - New Evidence Using Linked R&D-LRD Data |
6 |
13 |
57 |
273 |
9 |
28 |
103 |
469 |
| The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis |
3 |
6 |
16 |
136 |
14 |
33 |
99 |
492 |
| The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth |
4 |
10 |
45 |
45 |
11 |
29 |
95 |
95 |
| The expanding pharmaceutical arsenal in the war on cancer |
1 |
4 |
12 |
94 |
5 |
17 |
54 |
369 |
| The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001 |
0 |
3 |
19 |
172 |
1 |
8 |
50 |
496 |
| Training, Tenure, and Productivity |
1 |
3 |
9 |
45 |
6 |
17 |
32 |
147 |
| USING LINKED CENSUS R&D-LRD DATA TO ANALYZE THE EFFECT OF R&D INVESTMENT ON TOTAL FACTOR PRODUCTIVITY GROWTH |
1 |
2 |
13 |
325 |
1 |
6 |
26 |
575 |
| Using Patents Data to Map Technical Change in Health-Related Areas |
0 |
3 |
6 |
89 |
2 |
5 |
16 |
196 |
| Total Working Papers |
74 |
214 |
823 |
7,298 |
341 |
944 |
3,287 |
31,051 |
| Journal Article |
File Downloads |
Abstract Views |
| Last month |
3 months |
12 months |
Total |
Last month |
3 months |
12 months |
Total |
| Benefits and costs of newer drugs: an update |
2 |
3 |
11 |
46 |
3 |
15 |
51 |
170 |
| Benefits and costs of newer drugs: an update |
2 |
4 |
13 |
34 |
5 |
13 |
37 |
95 |
| Book Reviews |
0 |
0 |
1 |
1 |
0 |
0 |
2 |
2 |
| Changing market opportunities and the structure of R & D investment: The case of energy |
0 |
0 |
1 |
5 |
0 |
1 |
5 |
36 |
| Computer Use and Productivity Growth in US Federal Government Agencies, 1987-92 |
0 |
0 |
2 |
44 |
1 |
3 |
14 |
279 |
| Contributions to Federal Election Campaigns by Government Contractors |
0 |
0 |
1 |
12 |
0 |
1 |
13 |
251 |
| Do (More and Better) Drugs Keep People Out of Hospitals? |
1 |
1 |
29 |
208 |
4 |
8 |
73 |
489 |
| Does Foreign Direct Investment Transfer Technology Across Borders? |
4 |
9 |
42 |
328 |
11 |
26 |
105 |
801 |
| Energy prices and induced innovation |
0 |
2 |
11 |
33 |
0 |
3 |
15 |
49 |
| Errors of Measurement in Output Deflators |
0 |
0 |
0 |
0 |
0 |
1 |
15 |
134 |
| Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data |
0 |
0 |
3 |
16 |
0 |
1 |
11 |
107 |
| Has Using Newer Drugs Reduced Admissions to Hospitals and Nursing Homes? |
0 |
0 |
1 |
12 |
0 |
0 |
12 |
44 |
| Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country-level data on 20 OECD countries, 1995-2003 |
2 |
2 |
7 |
7 |
13 |
34 |
74 |
74 |
| How elastic is the government's demand for weapons? |
0 |
2 |
2 |
5 |
0 |
3 |
7 |
29 |
| IMPORTATION AND INNOVATION |
1 |
1 |
2 |
16 |
5 |
14 |
41 |
112 |
| IR & D project data and theories of R & D investment |
0 |
0 |
1 |
3 |
0 |
1 |
5 |
27 |
| Industrial de-diversification and its consequences for productivity |
1 |
1 |
6 |
25 |
3 |
4 |
19 |
91 |
| Information technology and its impact on firm-level productivity: evidence from government and private data sources, 1977-1993 |
0 |
1 |
6 |
155 |
1 |
5 |
21 |
534 |
| Interindustry Technology Flows and Productivity Growth: A Re-examination |
0 |
3 |
22 |
139 |
0 |
4 |
47 |
335 |
| International R&D spillovers: A comment |
2 |
5 |
24 |
118 |
5 |
16 |
62 |
301 |
| Issues in measuring industrial R&D |
1 |
1 |
1 |
16 |
1 |
1 |
5 |
46 |
| Labour market institutions, liquidity constraints, and macroeconomic stability |
0 |
1 |
2 |
6 |
0 |
1 |
3 |
42 |
| Managerial ownership and firm performance: A re-examination using productivity measurement |
1 |
6 |
25 |
99 |
1 |
10 |
53 |
198 |
| Ownership structure and corporate performance in Japan |
1 |
2 |
11 |
72 |
5 |
11 |
32 |
197 |
| Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data |
0 |
1 |
6 |
6 |
2 |
8 |
32 |
32 |
| Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health' |
0 |
3 |
9 |
21 |
3 |
10 |
41 |
95 |
| Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health' |
0 |
3 |
7 |
22 |
2 |
11 |
36 |
87 |
| Productivity and Changes in Ownership of Manufactoring Plants |
0 |
3 |
18 |
41 |
2 |
9 |
60 |
134 |
| Rejoinder to comment by Maarten Vendrik |
0 |
1 |
3 |
6 |
1 |
5 |
14 |
58 |
| Sources of U.S. longevity increase, 1960-2001 |
1 |
2 |
12 |
57 |
1 |
3 |
26 |
239 |
| THE EFFECT OF CONTROL CHANGES ON THE PRODUCTIVITY OF U.S. MANUFACTURING PLANTS |
0 |
3 |
10 |
10 |
0 |
4 |
15 |
15 |
| Testing the Convergence Hypothesis |
3 |
9 |
33 |
209 |
7 |
27 |
127 |
818 |
| The Comparative Advantage of Educated Workers in Implementing New Technology |
3 |
15 |
40 |
456 |
8 |
32 |
112 |
2,602 |
| The Effect of Government Funding on Private Industrial Research and Development: A Re-assessment |
1 |
3 |
22 |
107 |
3 |
6 |
68 |
293 |
| The Effect of Ownership Changes on the Employment and Wages of Central Office and Other Personnel |
0 |
0 |
0 |
0 |
3 |
5 |
29 |
330 |
| The Effects of Medicare on Health Care Utilization and Outcomes |
0 |
4 |
26 |
79 |
4 |
36 |
217 |
499 |
| The Impact and Organization of Publicly-Funded Research and development in the European Community |
0 |
2 |
3 |
3 |
1 |
7 |
12 |
12 |
| The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001 |
1 |
11 |
18 |
56 |
1 |
14 |
33 |
154 |
| The Impact of New Drugs on US Longevity and Medical Expenditure, 1990–2003: Evidence from Longitudinal, Disease-Level Data |
1 |
2 |
10 |
12 |
3 |
4 |
21 |
112 |
| The Impact of R&D Investment on Productivity--New Evidence Using Linked R&D-LRD Data |
0 |
0 |
0 |
0 |
6 |
14 |
81 |
535 |
| The Managerial Response to Regulation of Financial Reporting for Segments of a Business Enterprise |
0 |
0 |
0 |
1 |
3 |
10 |
43 |
283 |
| The Private R&D Investment Response to Federal Design and Technical Competitions |
0 |
0 |
17 |
53 |
8 |
11 |
48 |
300 |
| The Relationship between Federal Contract R&D and Company R&D |
0 |
0 |
0 |
9 |
2 |
8 |
59 |
253 |
| The benefits to society of new drugs: a survey of the econometric evidence |
0 |
2 |
8 |
55 |
1 |
5 |
29 |
255 |
| The burden of government:, Stanford: Hoover Institution Press, 1986. x + 188 pp., $23.95 |
0 |
0 |
0 |
2 |
0 |
0 |
4 |
25 |
| The effect of new drug approvals on HIV mortality in the US, 1987-1998 |
0 |
0 |
2 |
11 |
0 |
1 |
9 |
78 |
| The effects of leveraged buyouts on productivity and related aspects of firm behavior |
3 |
11 |
46 |
342 |
7 |
23 |
102 |
764 |
| Total Journal Articles |
31 |
119 |
514 |
2,958 |
126 |
429 |
1,940 |
12,416 |
LogEc is hosted by the
Swedish Business School at Örebro University.